Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

PDC-1421 · BLI-1005

Other · Inhibitor of norepinephrine transporter (NET) (SLC6A2) · developed by BioLite

Phase 2 Most advanced trial (none active)
1 Registered trials

What is PDC-1421?

PDC-1421 is a botanical formulation containing extract of Radix polygalae (Polygala tenuifolia Willd.) that inhibits the norepinephrine transporter (NET), blocking norepinephrine reuptake and increasing norepinephrine availability for adrenergic neurotransmission. It is being studied for attention-deficit hyperactivity disorder (ADHD).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BLI-1005, Extract of Radix Polygalae
Drug type
Other
Targets
norepinephrine transporter (NET) (SLC6A2)
Mechanism
Inhibitor of norepinephrine transporter (NET) (SLC6A2)
Pathways
norepinephrine reuptake inhibition, adrenergic neurotransmission
Therapy area
Psychiatry
Developer
BioLite, Inc.
In trials of
ABVC
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
5S7W573MTU

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05202327 Phase 2 Attention-Deficit Hyperactivity Disorder (ADHD) Completed ABVC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Attention-Deficit Hyperactivity Disorder (ADHD)

Other drugs acting on SLC6A2

Atomoxetine FDA approved Bupropion FDA approved Solriamfetol FDA approved CTx-1301-Dexmethylphenidate Phase 3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.